Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor Agonist is Potentially Disease-Modifying in Parkinson’s Disease

New York, NY — April 29, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s, other diseases of the central nervous system (CNS) and various types of cancer, today announced the findings of a research study published in the current…